Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth

British Journal of Cancer volume 69, pages 620–621 (1994) Cite this article

Save article
View saved research

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Subjects

Authors
  1. I Cohen
    View author publications

    Search author on:PubMed Google Scholar

  2. DJD Rosen
    View author publications

    Search author on:PubMed Google Scholar

  3. M Altaras
    View author publications

    Search author on:PubMed Google Scholar

  4. Y Beyth
    View author publications

    Search author on:PubMed Google Scholar

  5. J Shapira
    View author publications

    Search author on:PubMed Google Scholar

  6. D Yigael
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, I., Rosen, D., Altaras, M. et al. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth. Br J Cancer 69, 620–621 (1994). https://doi.org/10.1038/bjc.1994.116

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/bjc.1994.116

Search

Advanced search

Quick links